Because TRAIL specifically stimulates cell death targeting tumor cells while sparing healthy cells, extensive studies have focused on exploiting agonistic antibodies against DR and recombinant TRAIL protein to achieve high therapeutic potential. The gene discussed is TNFSF10; the disease is neoplasm.